drugset / Trial / NCT05950776
COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults
Phase 2
Withdrawn
University Medical Center Hamburg-Eppendorf
CTC-NORTH · collabGerman Center for Infection Research · collabLudwig-Maximilians - University of Munich · collabPhilipps University Marburg · collabUniversity Hospital Tuebingen · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
In this multi-center phase II clinical trial, adults in stable health conditions will be vaccinated twice with either a low dose or high dose of the candidate vaccine MVA-SARS-2-S, or placebo. The aim of the study is to assess the safety and immunogenicity of the candidate vaccine.
Timeline
- Start
- 2021-01-15
- Primary completion
- 2022-11-02
- Completion
- 2022-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MVA-SARS-2-S | Vaccine | 1e+07 iu | — |
| Subject | MVA-SARS-2-S | Vaccine | 1e+08 iu | — |